BCAT-IN-4 - An Overview
The first conclusion level was the protection and tolerability of sifalimumab. Therapy-emergent adverse events (AEs) and severe AEs (SAEs) as well as their severity, final result, and any partnership towards the examine medication had been recorded by the investigator all over the research. AEs were being regarded as more likely to be associated wi